



Audited Financial Results for the Quarter & Year ended March 31, 2011.

CONSOLIDATED				Sr. No.	Particulars	COMPANY			
Rupees in Lacs [except for share data]						Rupees in Lacs [except for share data]			
3 Months Period ended on March 31, 2011	Corresponding 3 Months Period ended on March 31, 2010	Year to date figures for the current year ended on March 31, 2011	Year to date figures for the previous year ended on March 31, 2010	3 Months Period ended on March 31, 2011	Corresponding 3 Months Period ended on March 31, 2010	Year to date figures for the current year ended on March 31, 2011	Year to date figures for the previous year ended on March 31, 2010		
118,444	82,597	452,111	361,423	1	Sales & Income from operations :				
1,573	1,008	5,644	4,005	A	Gross Sales	51,453	43,065	221,129	185,491
116,871	81,589	446,467	357,418	B	Less : Excise Duty	969	490	3,506	2,198
4,420	3,068	16,552	11,267	C	Net Sales	50,484	42,575	217,623	183,293
121,291	84,657	463,019	368,685	D	Other Income from Operations	19,071	14,602	74,365	59,196
5,457	(5,044)	599	(11,334)	E	Total sales and other income from operations	69,555	57,177	291,988	242,489
27,664	25,262	100,711	89,089	2	Expenditure :				
10,693	8,841	46,228	40,080	A	Increase [-] / Decrease [+] in stock in trade & work in progress	304	(1,870)	(3,506)	(1,080)
19,516	11,031	60,892	44,869	B	Consumption of materials	19,508	18,115	67,670	61,748
3,174	3,979	12,692	13,389	C	Purchase of traded goods	5,168	2,808	22,830	16,119
35,179	25,632	151,970	125,114	D	Employees cost	13,215	7,526	38,724	27,790
101,683	69,701	373,092	301,207	E	Depreciation, Amortisation & Impairment	2,467	2,444	9,685	9,004
19,608	14,956	89,927	67,478	F	Other Expenditure	21,278	15,863	95,499	76,524
345	512	1,311	1,591	G	Total Expenditure	61,940	44,906	230,902	190,505
19,953	15,468	91,238	69,069	3	Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2]	7,615	12,271	61,086	51,984
1,898	1,575	7,804	8,092	4	Other Income	246	847	5,813	4,351
(1,601)	111	(812)	122	5	Profit before Interest & Exceptional Items [3 + 4]	7,861	13,118	66,899	56,335
297	1,686	6,992	8,214	6	A Interest & financial charges	904	906	3,950	4,263
19,656	13,782	84,246	60,855	B	Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans	(649)	(127)	(769)	45
0	0	0	(464)	C	Total Financial cost	255	779	3,181	4,308
19,656	13,782	84,246	60,391	7	Profit after Interest but before Exceptional Items [5 - 6]	7,606	12,339	63,718	52,027
1,040	677	10,636	7,407	8	Exceptional Items [-] Income / [-] Expense	0	0	0	0
18,616	13,105	73,610	52,984	9	Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8]	7,606	12,339	63,718	52,027
0	0	0	0	10	Tax expense	(1,370)	(760)	2,680	1,700
18,616	13,105	73,610	52,984	11	Net Profit [+] / Loss [-] from Ordinary Activities after tax [9 - 10]	8,976	13,099	61,038	50,327
(719)	(1,229)	(2,510)	(2,470)	12	Extraordinary items [net of tax expense]	0	0	0	0
17,897	11,876	71,100	50,514	13	Net Profit [+] / Loss [-] for the period [11 - 12]	8,976	13,099	61,038	50,327
10,237	6,824	20,237	15,030	14	Adjustments on consolidation [+] Income / [-] Expense	0	0	0	0
8,74	5,80 *	34,73	24,67 *	15	Net Profit [+] / Loss [-] for the period [13 + 14]	8,976	13,099	61,038	50,327
8,74	5,80 *	34,73	24,67 *	16	Paid-up equity share capital [Face Value Rs. 5 / -]	10,237	6,824	10,237	6,824
51,610,474	34,406,982	51,610,474	34,406,982	17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	198,754	155,390	198,754	155,390
25.21%	25.21%	25.21%	25.21%	18	Earnings Per Share [EPS] [For the period - not Annualised]:				
				A	Basic and Diluted EPS before Extraordinary Items [Rs.]	4.38	6.40 *	29.81	24.58 *
				B	Basic and Diluted EPS after Extraordinary Items [Rs.]	4.38	6.40 *	29.81	24.58 *
				19	Public shareholding :				
					- Number of shares	51,610,474	34,406,982	51,610,474	34,406,982
					- Percentage of Shareholding	25.21%	25.21%	25.21%	25.21%
				20	Promoters and Promoter group Shareholding :				
				A	Pledged / Encumbered :				
					- Number of Shares	Nil	Nil	Nil	Nil
					- Percentage of shares [as a % of the total shareholding of promoters and promoter group]	N.A.	N.A.	N.A.	N.A.
					- Percentage of shares [as a % of the total share capital of the company]	N.A.	N.A.	N.A.	N.A.
				B	Non-encumbered :				
					- Number of Shares	153,138,046	102,092,031	153,138,046	102,092,031
					- Percentage of shares [as a % of the total shareholding of promoters and promoter group]	100%	100.00%	100%	100%
					- Percentage of shares [as a % of the total share capital of the company]	74.79%	74.79%	74.79%	74.79%

Notes :

- The above results for the quarter / year ended on March 31, 2011 were reviewed by the Audit Committee on May 5, 2011 and then approved by the Board of Directors at their meeting held on May 6, 2011.
- In Consolidated Accounts, the accounts of foreign subsidiaries / a Joint Venture Company are audited up to December 31, 2010 and subjected to limited review by their auditors for the balance period up to March 31, 2011 wherever applicable.
- The Board of Directors have recommended a dividend of Rs. 6.25/- [@ 125%] per equity share on 204,748,520 equity shares of Rs. 5/- each for the financial year ended on March 31, 2011.
- * Earning per share in item 18 A & B for the three months period / year ended on March 31, 2010 is calculated taking into account the allotment of bonus shares issued by the company, to make the figures comparable.
- During the quarter the Company has entered into 50:50 Joint Venture with Bayer [South East Asia] Pte. Ltd., Singapore.
- The Company has incorporated Zydus Lanka [Private] Limited as a wholly owned subsidiary Company in Sri Lanka.
- The changes in Investments during the quarter are as under :

Zydus BSV Pharma Private Limited [Additional Investment]	Rs. 110 Lacs
Bayer Zydus Pharma Private Limited	Rs. 2500 Lacs
- The status of investor complaints :
Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 19, pending at the end of the quarter - Nil
- The Company has one segment of activity viz., "Pharmaceuticals".
- The detailed standalone results will be available on the Company's website : www.zyduscadila.com and / or on the website of BSE [www.bseindia.com] and / or NSE [www.nseindia.com]. The summarised Audited standalone financial results of the company are as below.

Audited Statement of Assets & Liabilities as at March 31, 2011						
CONSOLIDATED			Sr. No.	Particulars	COMPANY	
Rupees in Lacs					Rupees in Lacs	
Current accounting Year ended on March 31, 2011	Previous accounting Year ended on March 31, 2010		Current accounting Year ended on March 31, 2011	Previous accounting Year ended on March 31, 2010		
10,237	6,824	1	Shareholders' Funds :			
206,911	156,030	A	Capital	10,237	6,824	
109,734	109,054	B	Reserves and Surplus	198,754	155,390	
6,692	3,916	2	Loan Funds	56,400	59,409	
11,266	11,407	3	Minority Interest	0	0	
344,840	287,231	4	Deferred Tax Liability / (Asset)	11,930	11,491	
226,364	193,262	5	Total Sources of Funds	277,321	233,114	
2,069	2,069	6	Fixed Assets	127,032	109,326	
81,185	75,040	7	Investments	69,878	59,887	
76,524	46,677	8	Current Assets, Loans and Advances :			
29,520	25,072	A	Inventories	46,452	38,083	
41,063	31,204	B	Sundry Debtors	47,508	40,082	
		C	Cash and Bank Balances	4,238	2,822	
		D	Loans and Advances	50,608	36,774	
89,554	67,600	9	Less : Current Liabilities and Provisions			
22,331	19,509	A	Liabilities	50,355	38,808	
0	1,016	B	Provisions	18,040	15,168	
344,840	287,231	10	Foreign Currency Monetary Items Translation Difference Account	0	116	
		11	Total Application of Funds	277,321	233,114	

For Cadila Healthcare Limited,

Pankaj R. Patel
Chairman & Managing Director